Investors should consider Cullinan Therapeutics (CGEM) as a value opportunity, as the stock currently trades around $15 despite sophisticated institutional investors recently paying $19 per share. In the semiconductor space, Micron (MU) and SK Hynix remain high-conviction plays driven by intense AI demand and strong sector momentum. While Amgen (AMGN) is an "execution machine" with massive revenue from Repatha and Crystexa, investors should remain cautious and monitor upcoming data for their weight loss drug, MariTide. Vaxcyte (PCVX) offers high-reward potential and could "certainly double" if its pneumococcal vaccine successfully competes with Pfizer, though it remains a high-risk biotech play. For long-term growth in the weight loss sector, keep a close eye on Viking Therapeutics (VKTX) and its lead candidate VK2735, though full commercialization is not expected until 2027.

This analysis summarizes the investment insights and asset mentions from the Martin Shkreli podcast transcript dated 4/6/26.

Amgen (AMGN)

The speaker spent significant time discussing Amgen’s portfolio, specifically their execution in the metabolic and immunology space.

• Repatha: Described as a "monster" and "selling like crazy." It is a PCSK9 antibody used for cholesterol.
• Crystexa: A drug for gout acquired through the acquisition of Horizon (formerly Savient). Shkreli noted it is doing roughly $400 million in quarterly revenue ($1.6 billion annualized) and called Amgen an "execution machine."
• MariTide (AMG 133): A key focus for Amgen’s future growth in the GLP-1 (weight loss) space. It is a GIP receptor antagonist.

Takeaways

• Sentiment: Bullish on current execution, but cautious on the weight loss pipeline.
• Risk Factor: There is skepticism regarding MariTide’s safety and efficacy profile compared to Eli Lilly’s Zepbound (terzepatide). Consensus estimates are at $7 billion, but Shkreli is unsure if they will hit that mark.
• Action: Monitor upcoming data for MariTide to see if it can compete with established players.

Viking Therapeutics (VKTX)

Viking is a clinical-stage biopharmaceutical company focused on metabolic disorders.

• VK2735: Their lead GLP-1/GIP dual agonist for weight loss.
• Market Cap: Noted at approximately $4 billion, which Shkreli suggested is "not bad" for the potential value.

Takeaways

• Sentiment: Neutral to mildly positive.
• Insight: While the Phase 2 data looks good, the Phase 3 results are still a long way off (estimated 2027).
• Action: It is considered a "Novo Nordisk model" play, but investors should be aware of the long timeline before commercialization.

Micron (MU) & Memory Sector

The speaker briefly touched on the semiconductor and memory markets, noting high correlation between key players.

• Performance: Micron was noted as being up 5%, with the speaker stating the "whole market is basically Micron right now."
• SK Hynix: Mentioned alongside Micron as a leader in the space.

Takeaways

• Sentiment: Bullish on the sector's momentum, driven by AI demand.
• Insight: Shkreli noted that the stock charts for these memory companies are "superimposable," meaning they are trading in high correlation.

Vaxcyte (PCVX)

A vaccine-focused biotech company.

• Product: Developing a pneumococcal vaccine to compete with Pfizer’s Prevnar.
• Institutional Interest: Noted that high-profile healthcare hedge funds (RA Capital, DeepTrack, Adage) are heavily involved.

Takeaways

• Sentiment: Potentially Bullish but high risk.
• Insight: The stock "could certainly double," but it faces stiff competition from Pfizer and Merck.

Cullinan Therapeutics (CGEM)

Formerly Cullinan Oncology, now focused on broader therapeutic areas.

• Pipeline: Mentioned Zipalertinib (for lung cancer) and a pivot into autoimmune drugs.
• Financials: Recently completed a $280 million private placement at $19/share. The stock is currently trading around $15.

Takeaways

• Sentiment: Positive on the valuation gap.
• Insight: "Smart investors" were willing to pay $19 recently, while the market price is currently lower ($15), suggesting a potential value opportunity.

Investment Themes & Sectors

GLP-1 / Weight Loss Peptides

• The sector is moving toward "triple agonists" (targeting GLP-1, GIP, and Glucagon).
• Retatrutide (Eli Lilly): Mentioned as a powerful upcoming drug in Phase 3 trials.
• Risk: Shkreli warned about the "LARPing" in the peptide community, where individuals inject unapproved substances without medical supervision.

AI & Optical Computing

• QCLS / Spruce: Shkreli’s own ventures involving optical computing and AI.
• Timeline: He estimates that optical computing (displacing GPUs) is still "pre-commercial" and likely 2-3 years away from commercial viability, though not as far off as quantum computing.

Cryptocurrency

• Bitcoin (BTC): Mentioned briefly in the context of recent news, though no specific price targets were provided.

Other Mentions

• Soleno Therapeutics (SLNO): Mentioned regarding its acquisition by Neurocrine (NBIX).
• Lightwave Logic (LWLG): A $1.3 billion photonic device company noted for further research.
• Nvidia (NVDA): Noted as trading "flat" during the session.
• Kodiak Sciences (KOD): Expressed surprise that the company is still active despite previous setbacks.